// App-Quantinova.ai

AB0837 : ITCH AS THE MAJOR MEDIATOR OF THE EFFECT OF TOFACITINIB ON HEALTH-RELATED QUALITY OF LIFE IN PsA: A MEDIATION ANALYSIS

Researchers

Presenter

  • P. C. Taylor

Principal Investigators

  • A. G. Bushmakin

  • J. C. Cappelleri

  • P. Young

  • R. Germino

  • J. F. Merola

  • G. Yosipovitch

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Pfizer, Inc, Groton, CT, United States of America

  • Pfizer Inc., Collegeville, United States

  • Pfizer, Inc, New York, NY, United States of America

  • Harvard Medical School - Boston - United States of America

  • University of Miami - Miami - United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved